AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 31 min read$KMTS

Moran Timothy P. sold $348K of KMTS

Moran Timothy P. (Chief Business Officer) sold 15,256 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $22.83 ($22.61–$23.76, $0.35M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Moran Timothy P.
Published Aug 3, 2026, 11:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest information is the disclosed open-market sale amount, share count, and trade window by the CBO. Without additional company-specific catalysts, the trading impact is likely sentiment-driven rather than fundamental.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale alone is unlikely to change valuation absent other news.

03

What to watch

The filing does not state a 10b5-1 plan and includes multiple trade dates and prices, but it provides no reason for the sale or any concurrent corporate event.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-03 after-hours (SEC Form 4)

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CBO Timothy P. Moran sold $348,310.62 of KMTS shares in open-market trades from 2026-07-30 to 2026-08-03.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The transaction is an open-market sale with no 10b5-1 plan stated, but the article provides no accompanying earnings, guidance, deal, or regulatory catalyst.

Market effects

Sector

No sector-wide signal; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales are often routine for diversification or tax planning, so the market may discount the signal quickly.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Timothy P. Moran

    Chief Business Officer who sold shares via open-market transactions.

Read at source← All news

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min